Medical/Pharmaceuticals
Suvoda sets new standard for streamlined patient and site experience in clinical trials
CONSHOHOCKEN, Pa., Jan. 12, 2026 /PRNewswire/ -- Suvoda, a clinical trial technology company, took decisive steps in 2025 toward a more connected and streamlined clinical trial experience for both patients and sites. The company's merger with Greenphire marked a pivotal moment in that journey, s...
2026-01-12 23:00
11113
Basecamp Research launches world-first AI models for programmable gene insertion
* The breakthrough tackles a longstanding challenge in genetic medicine with the goal of developing a new generation of curative cell and gene therapies. * Developed in collaboration with NVIDIA by training the largest evolutionary AI models on a new, globally collected dataset, accelerated by...
2026-01-12 23:00
9767
Datasea Announces Major Acoustic Technology Advancements in Brain-Computer Interface Applications
Acoustic-Driven Technologies Poised to Support Embodied Intelligence and Health Robotics Applications in a Multi-Billion-Dollar Brain–Computer Interface Market BEIJING, Jan. 12, 2026 /PRNewswire/ -- Datasea Inc. (NASDAQ: DTSS) ("Datasea" or the "Company"), a technology company specializing in aco...
2026-01-12 22:30
7286
Deepson Bio Receives Presidential Award at 2025 Korea Invention Patent Exhibition
Award highlights promise of ultrasound-based innovation in addressing unmet needs in dementia treatment SEOUL, South Korea, Jan. 12, 2026 /PRNewswire/ -- Deepson Bio Co., Ltd., a medical technology company focused on ultrasound-based approaches to dementia treatment, was honored with the Preside...
2026-01-12 22:00
5305
LumiMind Wins SPEED AWARD at CES 2026 for Innovative Non-Invasive Sleep Technology With Real-Time EEG
LAS VEGAS, Jan. 12, 2026 /PRNewswire/ -- LumiMind, a next-generation
neurotechnology company advancing non-invasive brain health solutions, today
announced that it has won theSPEED AWARD at CES 2026 for its breakthrough
consumer sleep technology,LumiSleep.
2026-01-12 22:00
5435
Insilico Medicine Completes First Patient First Dose in BETHESDA: A Phase II Trial for Garutadustat (ISM5411), the Gut-restricted AI-driven PHD Inhibitor for the Treatment of Inflammatory Bowel Disease
CAMBRIDGE, Mass., Jan. 12, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico"),
a clinical-stage, generative AI-driven drug discovery company, today announced
the completion of first patient first dose in BETHESDA: a Phase IIa clinical
trial of ISM5411 (NCT07265570
2026-01-12 21:30
6026
WuXi Biologics Launches Industry-Leading Digital Twin Platform PatroLab™ Designed to Transform Bioprocessing and Manufacturing
SHANGHAI, Jan. 12, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced the launch of PatroLabTM, a state-of-the-art digital twin platform designed to transform bioprocess development and manufactur...
2026-01-12 21:09
8905
CARsgen and Dispatch Bio Announce Clinical Collaboration to Evaluate Flare Platform and Zevor-cel in Solid Tumors
SHANGHAI, PHILADELPHIA and SAN FRANCISCO, Jan. 12, 2026 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, and Dispatch Bio, a biotech company engineering a universal treatment across solid tumors leveragin...
2026-01-12 21:05
8307
Major global health grant awarded to Oktopi to accelerate equitable medicine development capability worldwide.
MELBOURNE, Australia, Jan. 12, 2026 /PRNewswire/ -- Oktopi has been awarded a significant grant from the Gates Foundation to advance global access to high-quality medicine development expertise, with a particular focus on supporting innovators in low- and middle-income countries (LMICs). This fu...
2026-01-12 21:00
9469
BostonGene Recognized by Frost & Sullivan for 2025 Global Technology Innovation Leadership in AI-Driven Precision Oncology Solutions
Reshaping the Global Drug Development Landscape with the Industry's Only
Natively AI-Powered Omnimodal Foundation Model for Tumor and Immune Biology
SAN ANTONIO, Jan. 12, 2026 /PRNewswire/ -- Frost & Sullivan
2026-01-12 21:00
10377
Leadgene Biosolutions Expands Its Product Portfolio Following Strategic Integration, Advancing Early-Stage Mixing and Long-Term Metabolic Insight
TAIPEI, Jan. 12, 2026 /PRNewswire/ -- Leadgene Biosolutions today announces the expansion of its product portfolio following its strategic integration into Leadgene Biomedical. The expanded portfolio supports both early-stage cell line development and long-term metabolic research, enabling resear...
2026-01-12 21:00
6384
Haisco Grants Global Rights of Innovative Drug HSK39004 to AirNexis in Deal Exceeding USD 1 Billion
HSK39004, a novel dual‑target therapy, aims to compete in the global COPD market, highlighting innovation and international capabilities BEIJING, Jan. 12, 2026 /PRNewswire/ -- On January 9, 2026, Haisco Pharmaceutical Group Co., Ltd. (Ticker Code: 002653) announced that it has entered into an ex...
2026-01-12 20:00
6188
Novo Nordisk's GLP‑1 RA--A Modern Treatment for Obesity Management--is Linked to Lower Household Spending on Alcohol and Tobacco
Real-world data analysis suggests that families with at least one member using Novo Nordisk's GLP‑1 RA for weight management tend to reduce spending on alcohol and cigarettes. JAKARTA, Indonesia, Jan. 12, 2026 /PRNewswire/ -- At the international scientific congress ObesityWeek® held late last y...
2026-01-12 18:29
9269
WuXi AppTec Issues Positive Profit Alert for the Full Year of 2025
SHANGHAI, Jan. 12, 2026 /PRNewswire/ -- WuXi AppTec (stock code: 603259.SH/2359.HK), a leading global pharmaceutical CRDMO (Contract Research, Development, and Manufacturing Organization), today issued a Positive Profit Alert for the full year of 2025, disclosing forecasts of key operational data...
2026-01-12 17:30
7278
Formosa Pharmaceuticals Announces Licensing Agreement with Samil Pharmaceuticals, Co., Ltd, for Commercialization of Clobetasol Propionate Ophthalmic Suspension for the Treatment of Inflammation and Pain Following Ocular Surgery
TAIPEI, Jan. 12, 2026 /PRNewswire/ -- Taiwan-based Formosa Pharmaceuticals ("Formosa", 6838.TW) announced today that the company has entered into an exclusive licensing agreement with Samil Pharmaceuticals, Co., Ltd ("Samil", 000520.KS), for exclusive rights to the commercialization of clobetasol...
2026-01-12 16:00
7849
Clover Initiates Phase 2 Clinical Trial for RSV + hMPV ± PIV3 Respiratory Combination Vaccine Candidates
-- Phase 2 Initiation Strengthens Global First-in-Class Potential for Clover's
Protein-Based RSV + hMPV ± PIV3 Respiratory Combination Vaccine Candidates --
SHANGHAI, Jan. 12, 2026 /PRNewswire/ -- Clover Biopharmaceuticals, Ltd.
2026-01-12 12:33
512
Zylox-Tonbridge Hosts Investor Open Day, Showcasing Innovation Pipeline and Global Growth Strategy
HANGZHOU, China, Jan. 11, 2026 /PRNewswire/ -- Zylox-Tonbridge Medical Technology Co., Ltd. (HKEX: 2190), a leading innovator in neurovascular and peripheral vascular interventional solutions, hosted its Investor Open Day at its Zhuhai Innovation Center, welcoming nearly 150 institutional investo...
2026-01-12 12:16
7968
Lynk Pharmaceuticals Announces Positive Phase III Topline Data of Zemprocitinib (LNK01001) in Rheumatoid Arthritis
HANGZHOU, China, SHANGHAI and BOSTON, Jan. 12, 2026 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as "Lynk Pharmaceuticals"), a clinical stage innovative drug development company focused on developing innovative therapies for immune and inflammatory diseases, today annou...
2026-01-12 08:00
11989
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
T. Rowe Price Investment Management, Inc. and Braidwell LP participate as new investors Stephen Williams, MD, Ph.D. joins as Chief Scientific Officer Rebecca Chambers and Frank Witney, Ph.D. appointed to Board of Directors FREMONT, Calif., Jan. 12, 2026 /PRNewswire/ -- Alamar Biosciences, Inc. ...
2026-01-12 05:15
11875
Nona Biosciences Enters into Collaboration Agreement with Link Cell Therapies to Advance CAR-T Cell Therapies
CAMBRIDGE, Mass., Jan. 9, 2026 /PRNewswire/ -- Nona Biosciences ("Nona"), a global biotechnology company advancing biologics discovery through innovative technology platforms, today announced that it has entered into a multi-target antibody discovery collaboration with Link Cell Therapies. This c...
2026-01-09 20:00
7151
Week's Top Stories
Most Reposted
Visa redefines its role in travel with the global expansion of Visa Destinations
[Picked up by 336 media titles]
2026-06-30 10:00Sustainable Tourism Academy Celebrates 3,000-User Milestone in First Year with ASEAN Expansion and New Language Support
[Picked up by 323 media titles]
2026-06-29 12:41
Agoda rolls out suite of new features focused on real-time updates and smarter trip planning
[Picked up by 321 media titles]
2026-07-01 10:00
On-us Brings Real-Time Smart E-Vouchers to Google Wallet, Giving Marketers a Live Read on Customer Behavior
[Picked up by 319 media titles]
2026-06-30 11:00
Avnet Brings Ecosystem Together to Scale Edge AI in Singapore
[Picked up by 305 media titles]
2026-06-30 09:00Most Read
JINRO, the World's No. 1 Soju Brand, Partners with V of BTS
2026-07-03 08:00
6245
/UPDATE TO VIDEO -- New York Stock Exchange/
2026-07-01 01:36
5846
Farmmi, Inc. Announces Launch of Proposed Public Offering
2026-06-27 08:01
5127
NYSE Content Update: Mobility Global Marks First Day as Public Company
2026-07-01 21:22
4547
